EMA Aesthetics launches BLA®PRINâ, a breakthrough in regenerative skincare technology

EMA Aesthetics has unveiled its new exosome platform, BLA®PRINâ, marking a step forward in regenerative aesthetics. The technology focuses on long-term skin quality rather than short-term fixes. Company leaders describe it as a shift towards longevity-led skincare solutions. The BLA®PRINâ exosomes are sourced from human umbilical cord blood plasma, obtained through accredited public cord blood banks. These exosomes undergo a proprietary purification process to maintain their structural integrity and biological activity. Standard methods, such as nanoparticle sizing and electron microscopy, have been used to characterise their properties.

In comparative studies, the platform demonstrated stronger regenerative effects at lower concentrations than other exosome treatments. The technology targets pathways linked to normal cell repair and function. According to Malcolm Wall Morris, Co-Founder and CEO of EMA Aesthetics, the launch establishes a unified scientific and brand framework for the company's exosome-based products.

The platform aims to set a new global benchmark for consistency, safety, and performance in exosome aesthetics. However, as of March 2026, no public partnerships with major cord blood banks or collection networks for sourcing plasma have been documented. The introduction of BLA®PRINâ aligns with the growing trend in regenerative aesthetics towards sustaining skin function over time. EMA Aesthetics positions the platform as a key development in exosome-based treatments. The company's focus remains on delivering measurable, long-term results in skincare.